ABSTRACT
Immunostimulatory sequences (ISS) are short DNA sequences containing unmethylated CpG dimers that have multiple effects on the host immune system, including the ability to stimulate antigen-specific cytotoxic T lymphocytes (CTLs) and drive Th1-type immune responses. Listeriolysin O (LLO)-containing pH-sensitive liposomes have been shown to efficiently deliver macromolecules to the cytosol of APCs and efficiently stimulate CTLs. We hypothesized that encapsulating ISS-oligodeoxyribonucleotides (ODNs) in this delivery system would enhance the cell-mediated immune response and skew Th1-type responses in protein antigen-based vaccination utilizing LLO-liposomes. In vitro studies indicated that coencapsulation of ISS in LLO-liposomes engendered activation of the NF-κB pathway while maintaining the efficient cytosolic delivery of antigen mediated by the coencapsulated LLO. Antigen-specific CTL responses monitored by using the model antigen ovalbumin (OVA) in mice were enhanced when mice were immunized with OVA and ISS-ODN-containing LLO-liposomes compared with those immunized with OVA-containing LLO-liposomes. The enhanced immune responses were of the Th1-type as monitored by the robust OVA-specific IgG2a induction and the OVA CD8 peptide-stimulated IFN-γ secretion. Our study suggests that including ISS-ODN in LLO-containing pH-sensitive liposomes yields a vaccine delivery system that enhances the cell-mediated immune response and skews this response toward the Th1-type.
Subject(s)
Bacterial Toxins/chemistry , Heat-Shock Proteins/chemistry , Hemolysin Proteins/chemistry , Liposomes/chemistry , Oligodeoxyribonucleotides/chemistry , Oligodeoxyribonucleotides/pharmacology , T-Lymphocytes, Cytotoxic/drug effects , Th1 Cells/drug effects , Th1 Cells/metabolism , Adjuvants, Immunologic/chemistry , Adjuvants, Immunologic/pharmacology , Animals , Cells, Cultured , Enzyme-Linked Immunosorbent Assay , Female , Interferon-gamma , Interleukin-12/metabolism , Mice , Mice, Inbred C57BL , T-Lymphocytes, Cytotoxic/metabolismABSTRACT
Immunostimulatory DNA containing unmethylated CpG motifs is recognized by Toll-like receptor 9, resulting in the activation of innate immune responses that subsequently amplify the adaptive-immune response. Advances in the characterization of Toll-like receptor 9 signaling have identified immunostimulatory sequences (ISS) with distinct biological activities. Numerous animal models have demonstrated that synthetic ISS are effective adjuvants that enhance both humoral and cellular immune responses in diverse indications, ranging from infectious disease to cancer and allergy. An added benefit supporting the use of ISS as a vaccine adjuvant is that the specific activation of a pathway critical to the regulation of the immune response results in minimal toxicity. To date, clinical testing has largely affirmed the potency and safety of ISS-adjuvanted vaccines.
Subject(s)
Adjuvants, Immunologic/administration & dosage , Vaccines, DNA/administration & dosage , Animals , CpG Islands/immunology , Humans , Toll-Like Receptor 9/administration & dosage , Toll-Like Receptor 9/immunology , Vaccines, DNA/immunologyABSTRACT
Approved influenza vaccines based on the induction of antibodies to hemagglutinin are strain specific and cumbersome to manufacture. Several alternative vaccine strategies based on the induction of humoral responses against the external domain of the M2 protein, as well as cellular responses against nucleoprotein, have the potential to target multiple strains of influenza. A universal vaccine would be a major advancement in the prevention of influenza infection as it would alleviate the need for tailored vaccines to control seasonal influenza epidemics while simultaneously providing a level of protection against potential pandemic strains.
Subject(s)
Influenza A virus/classification , Influenza A virus/immunology , Influenza Vaccines/immunology , Influenza, Human/prevention & control , Influenza, Human/virology , Animals , Antibody Formation/immunology , Antigens, Viral/chemistry , Antigens, Viral/immunology , CD8-Positive T-Lymphocytes/immunology , Humans , Influenza A virus/chemistry , Influenza, Human/immunology , Species SpecificityABSTRACT
CpG-C are a novel class of CpG motif-containing immunostimulatory sequences (ISS) that includes both a 5'-TCG element and a CpG-containing palindrome. CpG-C drive all known ISS activities and, in particular, are potent enhancers of IFN-alpha from plasmacytoid dendritic cells (PDCs). In our examination of CpG-C sequence requirements, we determined that optimal IFN-alpha-inducing activity could be achieved with longer palindromes. Longer palindromes also correlated with maintenance of the double-stranded (ds) form despite concentration and pH changes, indicating a preference for ds oligodeoxynucleotides (ODNs) by the ISS-induced signaling mechanism for IFN-alpha synthesis. This correlation did not hold for all arms of the ISS-induced immune response, since we did not observe increased B cell activity with the longer palindrome CpG-C ODNs. We further demonstrated that CpG-C retained activity in an in vitro primate system and induced the expression of several cytokines and IFN-alpha-inducible genes when CpG-C were administered in vivo to mice and primates. In conclusion, we have shown CpG-C to exert several types of immune functions across multiple species, and this novel class is thus an attractive candidate for ISS-based therapeutic strategies.
Subject(s)
Adjuvants, Immunologic/pharmacology , B-Lymphocytes/drug effects , Cytokines/biosynthesis , Gene Expression/drug effects , Oligodeoxyribonucleotides/pharmacology , Adjuvants, Immunologic/genetics , Animals , Apoptosis Regulatory Proteins , B-Lymphocytes/immunology , Cell Proliferation , CpG Islands/genetics , Female , GTP-Binding Proteins/biosynthesis , GTP-Binding Proteins/genetics , Gene Expression/physiology , Gene Expression Regulation/physiology , Humans , Interferon-alpha/metabolism , Interferon-gamma/metabolism , Interleukin-12/metabolism , Interleukin-6/metabolism , Lymph Nodes/chemistry , Lymph Nodes/metabolism , Mice , Myxovirus Resistance Proteins , Oligodeoxyribonucleotides/genetics , Papio , RNA, Messenger/analysis , RNA, Messenger/metabolism , RNA-Binding Proteins , Transcription Factors/biosynthesis , Transcription Factors/geneticsABSTRACT
The immunostimulatory effects of bacterial DNA on mammalian cells have been localized to unmethylated CpG motifs, and synthetic CpG-containing oligodeoxynucleotides that mimic these effects are known as immunostimulatory sequences (ISS). We have found that the polycationic antibiotic, polymyxin B (PMXB), associates with ISS and serum albumin in vitro and forms microparticles that greatly increase the activity of ISS on plasmacytoid dendritic cells (PDCs). Specifically, ISS/PMXB greatly enhanced IFN-alpha production from PDCs and other activities downstream of IFN-alpha, including IFN-gamma secretion, NK lytic activity, and the expression of genes dependent upon IFN-alpha/IFN-gamma. This amplification was specific for the IFN-alpha pathway since other ISS activities, including B cell proliferation, B cell IL-6 secretion, and PDC maturation, were not affected by PMXB. Both the polycationic peptide and lipophilic fatty acid side chain domains of PMXB, as well as the presence of a third party stabilizing agent such as albumin or Tween 85, were required for particle formation and enhanced ISS activity. The ISS-enhancing activity of PMXB was observed across multiple species (human, primate, and mouse) and in vivo (primate, mouse). These data illustrate the usefulness of formulating ISS with a cationic lipopeptide such as PMXB, which focuses and greatly amplifies the ISS-induced pathway of IFN-alpha-mediated responses.
Subject(s)
Anti-Bacterial Agents/pharmacology , Oligodeoxyribonucleotides/pharmacology , Polymyxin B/pharmacology , Animals , CpG Islands/drug effects , CpG Islands/immunology , Dendritic Cells/immunology , Enzyme-Linked Immunosorbent Assay , Female , Hepatitis B Surface Antigens/biosynthesis , Hepatitis B Surface Antigens/immunology , Humans , Immunoglobulin G/biosynthesis , Immunoglobulin G/immunology , Interferon-alpha/biosynthesis , Interferon-alpha/immunology , Interferon-gamma/metabolism , Killer Cells, Natural/drug effects , Killer Cells, Natural/immunology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/immunology , Male , Mice , Mice, Inbred BALB C , Oligodeoxyribonucleotides/immunology , Papio , Serum Albumin/immunology , Statistics, NonparametricABSTRACT
Synthetic oligonucleotides containing CpG motifs in specific sequence contexts have been shown to induce potent immune responses. We have evaluated mucosal administration of two immunostimulatory sequence (ISS)-containing phosphorothioate-stabilized oligonucleotides for antiherpetic efficacy in animal models. The ISS oligonucleotides, suspended in phosphate-buffered saline, were tested in mouse and guinea pig vaginal models of herpes simplex virus type 2 (HSV-2) infection. For comparison, groups of untreated, non-ISS oligonucleotide-treated, and acyclovir-treated animals also were monitored. The results indicated that vaginal epithelial application of ISS (up to 6 h after viral inoculation) with mice lethally challenged with HSV-2 delayed disease onset and reduced the number of animals that developed signs of disease (P = 0.003). ISS application significantly increased survival rates over those of controls (P = 0.0014). The ISS also impacted an established infection in the guinea pig model of HSV-2 disease. A single administration of ISS (21 days after viral inoculation) significantly reduced the frequency and severity of HSV-2 lesions compared to results with non-ISS oligonucleotide-treated and untreated guinea pigs (P < 0.01). HSV-2 is shed from the vaginal cavity of the guinea pig in the absence of lesions, similar to the case with humans. As an additional indication of ISS efficacy, the magnitude of viral shedding also was significantly reduced in ISS-treated animals (P < 0.001). These effects appeared to be immunologically mediated, since ISS had no direct effect on HSV-2 replication in vitro using standard plaque assays. These data suggest that ISS may be useful in the treatment and control of genital herpes in humans.